The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00338338|
Recruitment Status : Completed
First Posted : June 20, 2006
Last Update Posted : October 9, 2017
|Condition or disease||Intervention/treatment||Phase|
|Uncomplicated Hypertension Hypertension Essential||Drug: Lacidipine 4 or 6 mg (oral) Drug: Amlodipine 5 or 10 mg(oral)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-blind, Parallel Group, Single-Centre Study to Evaluate the Efficacy and Safety of Lacidipine and Amlodipine Once-daily Treatment in Hypertensive Adult Patients|
|Actual Study Start Date :||November 7, 2005|
|Primary Completion Date :||September 14, 2007|
|Study Completion Date :||September 14, 2007|
Drug: Lacidipine 4 or 6 mg (oral)
Drug: Amlodipine 5 or 10 mg(oral)
- To evaluate the efficacy of of Lacidipine 4 or 6 mg and Amlodipine 5 or 10 mg on blood pressure profiles, in terms of blood pressure, heart rate, and edema after 8 weeks of treatment.
- To compare the overall safety profile of Lacidipine and Amlodipine, in terms of percentage and types of adverse events reported after 8 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00338338
|GSK Investigational Site|
|Taipei, Taiwan, 100|
|Study Director:||GSK Clinical Trials, MD, PhD||GlaxoSmithKline|